The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes

Thirty patients with myelodysplastic syndromes (MDS) were treated with thalidomide at 100 mg/d p.o., increased as tolerated to 400 mg/d for 12 weeks. Levels of apoptosis, macrophage number, microvessel density (MVD), tumour necrosis factor alpha (TNF‐α), transforming growth factor beta (TGF‐β), inte...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2001-12, Vol.115 (4), p.881-894
Main Authors: Zorat, Francesca, Shetty, Vilasini, Dutt, Diya, Lisak, Laurie, Nascimben, Fabiana, Allampallam, Krishnan, Dar, Saleem, York, Aaron, Gezer, Sefer, Venugopal, Parameswaran, Raza, Azra
Format: Article
Language:English
Subjects:
Aged
Antineoplastic agents
Biological and medical sciences
Case-Control Studies
Chemotherapy
Cytokines - analysis
Cytokines - blood
Endothelial Growth Factors - blood
Female
Hematology
Hemoglobins - analysis
Humans
Immunosuppressive Agents - therapeutic use
Lymphokines - blood
Male
Medical sciences
Myelodysplastic syndromes
Myelodysplastic Syndromes - blood
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - immunology
Pharmacology. Drug treatments
Platelet Count
Remission Induction
thalidomide
Thalidomide - therapeutic use
Transforming Growth Factor alpha - blood
transforming growth factor beta
Transforming Growth Factor beta - analysis
vascular endothelial growth factor
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thirty patients with myelodysplastic syndromes (MDS) were treated with thalidomide at 100 mg/d p.o., increased as tolerated to 400 mg/d for 12 weeks. Levels of apoptosis, macrophage number, microvessel density (MVD), tumour necrosis factor alpha (TNF‐α), transforming growth factor beta (TGF‐β), interleukin 6 (IL‐6), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were determined in the serum, bone marrow (BM) plasma and BM biopsies before and after therapy. Pretherapy biological characteristics of MDS patients were compared with similar studies performed in 11 normal volunteers. Ten patients demonstrated haematological improvement in the erythroid series, six becoming transfusion independent. Responders had a higher pretherapy platelet count (P 
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.2001.03204.x